CD7 CAR-T Therapy

CD7 is a special protein found on most cancer cells in T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma. This makes CD7 a very good target for CAR-T cell therapy, which uses the patient’s own immune T cells to fight cancer. However, because CD7 is also on many normal T cells, scientists must carefully change the CAR-T cells to stop them from attacking themselves. This careful change is called gene deletion or blocking CD7 on the CAR-T cells to keep them safe.

CD7 CAR-T Therapy is used for

How CD7 CAR-T Therapy works

Doctors take T cells from the patient or a donor
The T cells are modified to carry a receptor (CAR) that targets CD7 on cancer cells
At the same time, CD7 on the CAR-T cells is deleted or blocked to prevent the CAR-T cells from attacking each other
These safe CAR-T cells are given back to the patient
The CAR-T cells find and kill cancer cells with CD7, helping to clear leukemia or lymphoma
This therapy has shown promising success with many patients responding well

Advantages of CD7 CAR-T Therapy

Our Advantages

Advanced Gene Editing: Immuno Vector precisely deletes or blocks CD7 in CAR-T cells to keep them safe
Strong Anti-Cancer Power: Our CD7 CAR-T cells are designed to effectively kill T-cell cancers
Personalized Treatment: We tailor therapies for the best patient outcomes
Safety Commitment: We minimize risks like CAR-T self-attack for safer therapy
Ongoing Support: Immuno Vector assists patients throughout treatment to help them heal